SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Baselga José)
 

Search: WFRF:(Baselga José) > (2015-2019) > PI3K inhibition res...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer

Bosch Campos, Ana (author)
Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Molekylära behandlingsstrategier vid bröstcancer,Forskargrupper vid Lunds universitet,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Molecular therapeutics in breast cancer,Lund University Research Groups,Memorial Sloan-Kettering Cancer Center
Li, Zhiqiang (author)
Memorial Sloan-Kettering Cancer Center
Bergamaschi, Anna (author)
University of Illinois at Urbana-Champaign
show more...
Ellis, Haley (author)
Memorial Sloan-Kettering Cancer Center
Toska, Eneda (author)
Memorial Sloan-Kettering Cancer Center
Prat, Aleix (author)
Hospital Clínic of Barcelona
Tao, Jessica J. (author)
Massachusetts General Hospital
Spratt, Daniel E. (author)
Memorial Sloan-Kettering Cancer Center
Viola-Villegas, Nerissa T. (author)
Karmanos Cancer Institute
Castel, Pau (author)
Memorial Sloan-Kettering Cancer Center
Minuesa, Gerard (author)
Memorial Sloan-Kettering Cancer Center
Morse, Natasha (author)
Memorial Sloan-Kettering Cancer Center
Rodón, Jordi (author)
Autonomous University of Barcelona
Ibrahim, Yasir (author)
Vall d'Hebron University Hospital
Cortes, Javier (author)
Vall d'Hebron University Hospital
Perez-Garcia, Jose (author)
Vall d'Hebron University Hospital
Galvan, Patricia (author)
Vall d'Hebron University Hospital
Grueso, Judit (author)
Vall d'Hebron University Hospital
Guzman, Marta (author)
Vall d'Hebron University Hospital
Katzenellenbogen, John A. (author)
University of Illinois at Urbana-Champaign
Kharas, Michaelz (author)
Memorial Sloan-Kettering Cancer Center
Lewis, Jason S. (author)
Memorial Sloan-Kettering Cancer Center
Dickler, Maura (author)
Memorial Sloan-Kettering Cancer Center
Serra, Violeta (author)
Vall d'Hebron University Hospital
Rosen, Neal (author)
Memorial Sloan-Kettering Cancer Center
Chandarlapaty, Sarat (author)
Weill Cornell Medical College
Scaltriti, Maurizio (author)
Memorial Sloan-Kettering Cancer Center
Baselga, José (author)
Weill Cornell Medical College
show less...
 (creator_code:org_t)
American Association for the Advancement of Science (AAAS), 2015
2015
English.
In: Science Translational Medicine. - : American Association for the Advancement of Science (AAAS). - 1946-6234 .- 1946-6242. ; 7:283, s. 1-11
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Activating mutations of PIK3CA are the most frequent genomic alterations in estrogen receptor (ER)-positive breast tumors, and selective phosphatidylinositol 3-kinase a (PI3Kα) inhibitors are in clinical development. The activity of these agents, however, is not homogeneous, and only a fraction of patients bearing PIK3CA-mutant ER-positive tumors benefit from single-agent administration. Searching for mechanisms of resistance, we observed that suppression of PI3K signaling results in induction of ER-dependent transcriptional activity, as demonstrated by changes in expression of genes containing ER-binding sites and increased occupancy by the ER of promoter regions of upregulated genes. Furthermore, expression of ESR1 mRNA and ER protein were also increased upon PI3K inhibition. These changes in gene expression were confirmed in vivo in xenografts and patient-derived models and in tumors from patients undergoing treatment with the PI3Kα inhibitor BYL719. The observed effects on transcription were enhanced by the addition of estradiol and suppressed by the anti-ER therapies fulvestrant and tamoxifen. Fulvestrant markedly sensitized ER-positive tumors to PI3Kα inhibition, resulting in major tumor regressions in vivo. We propose that increased ER transcriptional activity may be a reactive mechanism that limits the activity of PI3K inhibitors and that combined PI3K and ER inhibition is a rational approach to target these tumors.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Medicinsk genetik (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Medical Genetics (hsv//eng)

Publication and Content Type

art (subject category)
ref (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view